Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression

@article{Eisele2014CilengitideTO,
  title={Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression},
  author={Günter Eisele and Antje Wick and A. Eisele and P. Clement and J{\"o}rg-Christian Tonn and Ghazaleh Tabatabai and Adrian F. Ochsenbein and Uwe Schlegel and Bart Neyns and Dietmar Krex and Matthias Simon and Guido Nikkhah and Martin Picard and Roger Stupp and Wolfgang Wick and Michael Weller},
  journal={Journal of Neuro-Oncology},
  year={2014},
  volume={117},
  pages={141-145}
}
The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma. Preclinical data as well as anecdotal clinical observations indicate that anti-angiogenic treatment may result in altered patterns of tumor progression. Using a standardized approach, we analyzed patterns of progression on MRI in 21 patients enrolled onto a phase 2 trial of cilengitide added to TMZ… Expand
Therapeutic approaches to overcome temozolomide resistance in glioblastoma
TLDR
Mechanisms linked to TMZ resistance are discussed and potential treatment options for patients with TMZ-resistant GBM are summarized, showing advances in identifying novel targets and potential molecular, pharmacological, immunological, and noninvasive therapies remain a hurdle in establishing long-term treatment for GBM patients. Expand
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
TLDR
A very detailed and exhaustive approach the literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 clinical trials on adults with newly diagnosed or recurrent GBMs (excluding targeted immunotherapies and therapies targeting tumor cell metabolism, well documented in recent reviews). Expand
Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis.
TLDR
This review will focus on the preclinical model systems used to evaluate TIM and explore the mechanisms that influence overall treatment efficacy and provide rationales for future drug combination approaches with antimetastatic agents to improve outcomes and reduce resistance. Expand
A comparative assessment of the effects of integrin inhibitor cilengitide on primary culture of head and neck squamous cell carcinoma (HNSCC) and HNSCC cell lines
TLDR
Cilengitide has significantly inhibited the proliferation of HNSCC cells in a dose-dependent way and RGD-containing small-molecule synthetic peptides might be considered in tumor chemotherapy in the near future. Expand
Recent advances in targeted therapy for glioblastoma
TLDR
This review provides up-to-date information on the drugs and their molecular targets, which are currently in different stages of clinical trials and would provide better therapy in the future. Expand
For the next trick: new discoveries in radiobiology applied to glioblastoma.
  • J. Debus, A. Abdollahi
  • Medicine
  • American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
  • 2014
TLDR
It becomes increasingly apparent that treatment of GBM needs to integrate therapies targeting all distinct pathophysiological features, and recent approaches in GBM therapy include inhibition of invasion, antiangiogenesis and stroma modulators, and activation of immune response. Expand
Development of targeted therapies in treatment of glioblastoma
TLDR
An up-to-date review of the current targeted therapies in GBM is provided, which include drugs directed against specific targets which play essential roles in the proliferation, survival, and invasiveness of GBM cells. Expand
The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance
TLDR
The role of the hypoxic microenvironment and SRC proto-oncogene non-receptor tyrosine kinase in the activation of radioresistance and invasion pathways of glioblastoma is described, providing updated evidences on the involvement of SRC in these processes. Expand
Recurrence Pattern Analysis of Primary Glioblastoma.
TLDR
Despite complete resection of contrast-enhancing tumor, most recurrences occurred locally, so patients with distant tumor recurrence demonstrated increased progression-free survival, and may need to shift toward a more aggressive supramarginal resection to gain local control. Expand
Identification of PIEZO1 as a potential prognostic marker in gliomas
TLDR
High PIEZO1 expression is closely associated with highly malignant gliomas and serves as a key factor involved in sensing mechanical properties in the tumour and can regulate both tumour cells and their microenvironment to promote glioma progression, and it is also a potential therapeutic target for the treatment ofgliomas. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.
  • M. Hegi, T. Gorlia, +16 authors M. Weller
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
CIL failed to prolong PFS or OS in patients with newly diagnosed glioblastoma and methylated MGMT gene promoter and the previously reported safety profile of CIL in addition to standard therapy was confirmed. Expand
A novel tool to analyze MRI recurrence patterns in glioblastoma.
TLDR
Analysis of recurrence patterns revealed no difference between the groups in the size of the recurrent tumor or in the differential effect on the distance of the recurrences from the preoperative tumor location, and the data show the feasibility of groupwise recurrence pattern analysis. Expand
Bevacizumab does not increase the risk of remote relapse in malignant glioma
TLDR
The risk of distant or diffuse recurrence at the time of failure of BEV‐containing treatments was not higher than with anti‐VEGF–free regimens, arguing against a specific property of BEv that promotes distant tumor growth or a gliomatosislike phenotype at recurrence. Expand
Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
TLDR
The AVAglio study adapted Macdonald criteria to address anti-angiogenic therapy/corticosteroid use by incorporating non-contrast-enhancing components and integrating a strict algorithm to standardize assessment of possible PsPD. Expand
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
  • J. Dignam, M. Won, +16 authors M. Mehta
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
The addition of Bev for newly diagnosed GBM did not improve OS, did improve PFS but did not reach the significance criterion, and risk subset results suggested strongly against the upfront use of BeV in the best prognosis pts. Expand
Invasion as limitation to anti-angiogenic glioma therapy.
TLDR
Tumor cell invasion was tightly associated with preexistent blood vessels, suggesting that increased cooption of the host vasculature could represent a compensatory mechanism that is selected for by inhibiting adequate tumor vascularization. Expand
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
TLDR
The present work underlines the need to combine anti-angiogenic treatment in GBMs with drugs targeting specific signaling or metabolic pathways linked to the glycolytic phenotype, and suggests that vascular remodeling induced by anti-VEGF treatment leads to a more hypoxic tumor microenvironment. Expand
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
TLDR
It is reported that angiogenesis inhibitors targeting the VEGF pathway demonstrate antitumor effects in mouse models of pancreatic neuroendocrine carcinoma and glioblastoma but concomitantly elicit tumor adaptation and progression to stages of greater malignancy, with heightened invasiveness and in some cases increased lymphatic and distant metastasis. Expand
Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma.
TLDR
It is reported that sublethal doses of irradiation enhance the migration and invasiveness of human malignant glioma cells and that the pharmacological inhibition of migration and invasion during radiotherapy may represent a new therapeutic approach to improve the therapeutic efficacy of radiotherapy for malignantglioma. Expand
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.
TLDR
This work presents a meta-analyses of the prophylactic and adjuvant properties ofatum-based chemotherapy on the basis of preoperatively diagnosed central giant cell granuloma in mice and shows clear prognosis for at-risk patients with atypical BMTs. Expand
...
1
2
...